ArticleMayo Clinic proceedings2023

SGLT2 Inhibitors Are Associated With Reduced Cardiovascular Disease in Patients With Type 2 Diabetes: An Analysis of Real-World Data.

Wendy Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.